Application of protocurcuma zedoary diol in preparation of medicine for preventing and / or treating hepatic fibrosis

Protocurdiodiol solves the treatment problem of liver fibrosis by targeting and regulating BEX1 protein in liver progenitor cells and inhibiting the PI3K/AKT signaling pathway, significantly improving liver function and pathological indicators, and is superior to existing drugs.

CN120617223APending Publication Date: 2025-09-12ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510902437.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-01
Publication Date
2025-09-12

AI Technical Summary

Technical Problem

Existing technologies lack effective drugs for the treatment and prevention of liver fibrosis, especially in developing countries and regions where the incidence and disease burden of liver fibrosis are serious. The traditional Chinese medicine Curcuma zedoaria is clinically used to treat liver fibrosis, but its specific mechanism of action is unclear.

Method used

Protocurdiodiol targets and regulates the expression of BEX1 protein in hepatic progenitor cells, inhibits the overactivation of the PI3K/AKT signaling pathway, inhibits the expression of hepatic progenitor cell activation markers and inflammatory factors, blocks the activation of hepatic stellate cells, and achieves a dose-dependent therapeutic effect.

Benefits of technology

Curcuma diol significantly inhibits liver fibrosis, downregulates BEX1 protein expression by ≥50%, improves liver function and pathological indicators, is superior to common drugs on the market, and effectively improves liver structure and function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120617223A_ABST
    Figure CN120617223A_ABST
Patent Text Reader

Abstract

The invention discloses application of protocurcuma zedoary diol in preparation of a medicine for preventing and / or treating hepatic fibrosis, and belongs to the technical field of medicines. Specifically speaking, it is found that the protocurcuma zedoary diol can inhibit activation of hepatic stellate cells by up-regulating expression of brain expression X-linked protein 1 (BEX1) and effectively improve liver function indexes and liver pathological states, so that the purpose of treating hepatic fibrosis is achieved. Experimental results show that the protocurcuma zedoary diol can remarkably inhibit proliferation of hepatic stellate cells in vitro and can remarkably reduce the serum transaminase level and the hepatic fibrosis degree of hepatic fibrosis model rats in vivo. The invention also discloses a pharmaceutical composition containing the protocurcuma zedoary diol. The original curcuma zedoary diol provides a new candidate medicine for treating hepatic fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an anti-liver fibrosis drug, in particular to an application of proto-curdodiol in the preparation of a drug for preventing and / or treating liver fibrosis, belonging to the technical field of medicine. Background Art

[0002] Liver fibrosis has always been a global public health issue, especially in developing countries and regions, where its incidence and disease burden are particularly severe. Liver fibrosis is the liver's pathological repair response to chronic damage, mainly manifested by excessive deposition of extracellular matrix in the liver, leading to the gradual destruction of liver structure and function. Traditional Chinese Medicine believes that the liver is responsible for dispersing and regulating Qi. If emotions are not smooth, diet is not regular, or external toxins are introduced, it can lead to liver Qi stagnation. Qi stagnation leads to blood stasis, and blood stasis stagnates inside the body, forming accumulations of masses over time. The spleen is responsible for transportation and transformation. If the spleen fails to transport water and dampness, it will accumulate into phlegm, and phlegm and blood stasis will further aggravate liver damage. The kidney is the foundation of congenital constitution. Kidney deficiency leads to insufficient essence and Qi, which cannot nourish the liver, resulting in liver malnutrition and worsening of the condition.

[0003] The traditional Chinese medicine Curcuma zedoaria is the dried rhizome of the Zingiberaceae plants Curcuma phaeocaulis Vai., Curcuma wangsiensis SG Lee et C F. Liang, or Curcuma wenyujin YHChen et C. Ling. It is warm in nature, pungent and bitter in flavor, and enters the spleen and liver meridians, purifying qi and dispersing blood stasis, relieving pain. The traditional Chinese medicine Trigonella ternate (Sparganium stoloniferum Buch.-Ham.) is the dried tuber of the Sparganium family. It is neutral in nature, pungent and bitter in flavor, and enters the liver and spleen meridians, purifying qi and dispersing blood stasis, relieving pain. Vinegar-processed Curcuma zedoaria and Trigonella ternate (Sparganium stoloniferum) can be directed into the liver meridian, enhancing its blood circulation and stasis-removing effects. Therefore, the vinegar-processed Curcuma zedoaria and Trigonella ternate herb pair is commonly used clinically to treat liver fibrosis caused by various etiologies.

[0004] BEX1 (Brain-Expressed X-linked Protein 1, BEX1) is a brain-expressed X-linked protein and a member of the BEX protein family. BEX1 participates in numerous biological processes, including cell differentiation, apoptosis, and proliferation, and plays a crucial role in a variety of diseases. Studies have shown that BEX1 may contribute to the pathogenesis of liver fibrosis and cirrhosis by regulating the activation of hepatic progenitor cells and hepatic stellate cells, as well as extracellular matrix deposition. In hepatitis, BEX1 may contribute to disease progression by modulating inflammatory responses or immune cell function. Although research on BEX1 in liver disease is still preliminary, altered expression in liver cancer and other liver diseases suggests that it may be a potential therapeutic target or diagnostic marker. A literature review revealed that BEX1 colocalizes with epithelial cell adhesion molecule (EpCAM) in hepatic progenitor cells, suggesting that BEX1 may participate in liver regeneration and fibrosis by regulating the function of hepatic progenitor cells. Further research is needed to uncover the specific molecular mechanisms of BEX1 in liver disease and its clinical implications. Summary of the Invention

[0005] The present invention aims to provide a use of proto-curdodiol in the preparation of a medicament for preventing and / or treating liver fibrosis.

[0006] The technical solution adopted by the present invention to solve its technical problem is:

[0007] A use of proto-curdodiol in the preparation of a medicament for preventing and / or treating liver fibrosis.

[0008] Preferably, the application is achieved by targeted regulation of BEX1 protein expression in hepatic progenitor cells and inhibition of overactivation of the PI3K / AKT signaling pathway.

[0009] Preferably, in the application, protocurediol inhibits the expression of hepatic progenitor cell activation markers (DLK1, EpCAM) in a dose-dependent manner.

[0010] Preferably, the use further comprises inhibiting the expression of inflammatory factors (TNF-α, IL-6 and IL-1β) in hepatic progenitor cells.

[0011] Preferably, the use further comprises inhibiting the expression of epithelial-mesenchymal transition marker proteins (N-cadherin, E-cadherin, Vimentin) of hepatic progenitor cells.

[0012] Preferably, the use further comprises inhibiting the activation of hepatic stellate cells (HSC).

[0013] A use of proto-curdodiol in the preparation of a drug for treating liver fibrosis associated with abnormal BEX1 expression, wherein the drug downregulates BEX1 protein expression in liver tissue by ≥50% (Western blot) and downregulates the p-AKT / AKT ratio to ±20% of the normal level.

[0014] Preferably, the serum ALT and AST levels in the drug-treated group decreased by ≥40% compared with the model group, and the collagen area ratio in the liver tissue decreased by ≥60% (Masson staining).

[0015] A pharmaceutical composition comprises proto-curcuma diol as an active ingredient and one or more pharmaceutically acceptable carriers or excipients.

[0016] Preferably, the composition is in the form of tablets, capsules, granules or injections.

[0017] A method for inhibiting the activation of hepatic progenitor cells, comprising: administering an effective amount of protocurdiol to the hepatic progenitor cells, activating BEX1 expression, blocking the PI3K / AKT signaling pathway, and inhibiting the release of inflammatory factors (TNF-α, IL-6, and IL-1β) and epithelial-mesenchymal transition (N-cadherin, E-cadherin, Vimentin).

[0018] The beneficial effects of the present invention are:

[0019] This invention reveals for the first time the mechanism of action of protocurdiodiol in treating liver fibrosis by downregulating the expression of BEX1 protein, providing a new target for the treatment of liver fibrosis; both at the cellular level and at the whole animal level, protocurdiodiol exhibits clear anti-liver fibrosis activity, can effectively inhibit the activation of liver progenitor cells and epithelial-mesenchymal transition, inhibit the activation of hepatic stellate cells, and significantly improve the liver function and pathological indicators of model animals.

[0020] Experiments have shown that curcuma diol is more effective in treating liver fibrosis than common anti-liver fibrosis drugs on the market. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0022] Figure 1 The results of the MTT assay for the toxicity of the main active ingredients of vinegar-processed Curcuma zedoariae Tripterygium wilfordii.

[0023] Figure 2This is a diagram for screening the best active ingredients of the vinegar-processed Curcuma Rhizoma and Trigonum multiflorum drug pair;

[0024] Figure 3 Figure 1 is a graph showing changes in mouse weight and liver index results, where A is the animal experiment flow chart, B is a graph showing changes in mouse weight, and C is the liver index; Note: * P<0.05, ** P<0.001, *** P < 0.0001;

[0025] Figure 4 The test results of serum biochemical indicators ALT (left) and AST (right) of mice in each group, Note: * P<0.05, ** P<0.01, *** P < 0.001;

[0026] Figure 5 Actual photos of mouse liver; HE and Masson staining;

[0027] Figure 6 This is the Western blot result of the improvement effect of curcuma diol on liver damage in mice;

[0028] Figure 7 This is the immunofluorescence staining image showing the improvement effect of curcuma diol on liver damage in mice;

[0029] Figure 8 The figure shows the Western blot results of proteins related to hepatic progenitor cell activation in the context of BEX1 knockout (sgBEX1) or overexpression (OE-BEX1);

[0030] Figure 9 Immunofluorescence staining of proteins related to hepatic progenitor cell activation in the context of BEX1 knockout (sgBEX1) or overexpression (OE-BEX1);

[0031] Figure 10 Figure 2 is the transcriptomic enrichment result diagram of differentially expressed genes in BEX1 knockout (sgBEX1) hepatic progenitor cells, where A is the PCA analysis result of transcriptional data of blank group, model group, and model + knockout group; B is the statistical result of differentially expressed genes in blank group / model group, model group / model + knockout group; CD is the volcano plot of differentially expressed genes in blank group / model group, model group / model + knockout group; E is the Venn diagram of differentially expressed genes in blank group / model group, model group / model + knockout group; F is the enrichment result diagram of differentially expressed genes in pathway;

[0032] Figure 11 This is a Western-blot experiment result showing that Bex1 inhibits the release of inflammatory factors from hepatic progenitor cells through the PI3K / AKT signaling pathway;

[0033] Figure 12 Figure 1 shows Western blot results of PI3K / AKT signaling pathway proteins in hepatic progenitor cells in the context of BEX1 knockout (sgBEX1) or overexpression (OE-BEX1). A shows the results of in vitro cell experiments, and B shows the results of in vivo experiments in a mouse model of liver fibrosis.

[0034] Figure 13 The figure shows the Western blot results of inflammatory factors (TNF-α, IL-6, and IL-1β) in hepatic progenitor cells in the background of BEX1 knockout (sgBEX1) or overexpression (OE-BEX1);

[0035] Figure 14 The figure shows the Western blot results of epithelial-mesenchymal transition (N-cadherin, E-cadherin, and Vimentin) in hepatic progenitor cells under the background of BEX1 knockout (sgBEX1) or overexpression (OE-BEX1);

[0036] Figure 15 This is the Western-blot detection result of proto-curdodiol regulating hepatic progenitor cells and inhibiting the activation of hepatic stellate cells. DETAILED DESCRIPTION

[0037] The technical solution of the present invention is further described in detail below through specific examples. It should be understood that the implementation of the present invention is not limited to the following examples, and any form of modification and / or change made to the present invention will fall within the scope of protection of the present invention.

[0038] In the present invention, unless otherwise specified, all parts and percentages are by weight, and the equipment and raw materials used are commercially available or commonly used in the art. The methods in the following examples are all conventional methods in the art unless otherwise specified.

[0039] Unless otherwise specified, the reagents used in the following examples can be purchased from conventional biochemical reagent stores.

[0040] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0041] Example 1 Experimental study on the activity of curcuma diol on WB-F344 (rat liver epithelial stem cells)

[0042] 1. Sample source: WB-F344 (rat liver epithelial-like stem cells) were purchased from Wuhan Punosai Life Science Technology Co., Ltd. Kaempferol, formononetin, ferulic acid, vanillin, p-hydroxybenzoic acid, p-hydroxybenzaldehyde, protocatechuic acid, p-coumaric acid, protocurdol, protocurdiodiol, curdylbicycloenone, curdol, β-elemene, germacrone, curdiodione, furadiene, curcumin, and vanillic acid were all purchased from Beijing BetterKang Biopharmaceutical Technology Co., Ltd. with a purity greater than or equal to 98%.

[0043] 2. Dosage Design: Prepare standard solutions at concentrations of 400, 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.65 μmol / L. Control: Complete medium. Model: 50 ng / mL HGF in complete medium. This experiment included blank, model, and drug groups at varying concentrations. Drug groups: 18 standard solutions at 25 μmol / L plus 50 ng / mL HGF in complete medium.

[0044] 3. Experimental methods and results

[0045] (1) Toxicity evaluation: WB-F344 cells cultured to the logarithmic growth phase were digested with trypsin and then added with complete culture medium to adjust the cell density to 2.5×10 4 Cells / mL were inoculated into 96-well plates, 200 μL of cell suspension was added to each well, and the cells were allowed to adhere. The concentrations of the prepared standards were 400, 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.65 μmol / L, respectively. The drug-containing culture medium at these concentrations was added to the 96-well plates to which the cells had adhered, and placed in an incubator for 24 hours. Then, 10 μL of MTT solution was added to each well under light-proof conditions. After incubation in the incubator for 4 hours, 150 μL of DMSO solution was added to each well, and its absorbance at a wavelength of 490 nm was detected. The OD values ​​of the main active ingredients of vinegar-processed Curcuma zedoariae Tripterygium wilfordii at different concentrations were as follows: Figure 1 shown.

[0046] Depend on Figure 1 As can be seen, treatment with a concentration of 400 μmol / L resulted in a cell death rate exceeding 50%, while treatment with concentrations of 200 μmol / L and 100 μmol / L also showed significant cytotoxicity. Therefore, lower concentrations of 12.5 μmol / L and 25 μmol / L, which were non-toxic to WB-F344 cells, were selected for subsequent experiments.

[0047] (2) Activity test: 18 candidate active ingredients were preliminarily screened using Western blot technology, such as Figure 2 .

[0048] Depend on Figure 2In the model group, the expression levels of hepatic progenitor cell activation markers SOX9, CK19, DLK1, EpCAM, and the target BEX1 were significantly upregulated (P<0.001). After drug intervention, the expression of HGF-induced hepatic progenitor cell activation markers was significantly inhibited (P<0.001). Protocurdiol was found to have the most significant inhibitory effect on regulating hepatic progenitor cell activation.

[0049] Example 2 Effect of Curcuma diol on Anti-liver Fibrosis in Vivo

[0050] 1. Sample source: Procurcumadiol used in the present invention has a CAS number of 129673-90-1 and is a commercially available product purchased from Beijing BetterKang Biopharmaceutical Technology Co., Ltd. with a purity greater than or equal to 98%.

[0051] 2. Dosage design: The dosage of curcuma diol was determined based on the content measurement of the previous topic and the conversion of the adult clinical dosage in the 2020 edition of the Chinese Pharmacopoeia. 40% carbon tetrachloride (3 mL / kg) was used for modeling. Male BALB / c mice were divided into the following 6 groups (n = 10 / group): control group (Control), model group (Model), and positive drug group (Positive) using colchicine (0.4 mg / kg), curcuma diol low-dose group (5 mg / kg), curcuma diol medium-dose group (10 mg / kg), curcuma diol high-dose group (15 mg / kg), and 0.25% CMC-Na.

[0052] 3. Experimental methods and results

[0053] (1) Mouse weight change chart and liver index results: Except for the normal control group, the other groups were treated with the above-mentioned regimen for eight weeks. The treatment group adopted the intervention administration method, once a day, and the modeling and administration were carried out simultaneously. During the experiment, the weight changes of the mice were regularly monitored, and free food and water were guaranteed. Figure 3 shown.

[0054] (2) Serum biochemical indices: The administration method of each group was the same as that of the above-mentioned 2-dose design. At the 9th week of the experimental period, blood was collected from the orbital venous plexus of each group of mice, and the blood was kept at room temperature for 30 minutes, centrifuged at 3000 rpm for 10 minutes, and the upper serum was collected. The levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) were measured using an automatic biochemical analyzer. Finally, the serum biochemical indices of mice in different groups were obtained as follows: Figure 4 shown.

[0055] Depend on Figure 4It can be seen that compared with the control group, the AST and ALT in the model group were significantly increased, and the administration of curcuma diol significantly downregulated them (P<0.05), and the high dose was more significant (P<0.001). Moreover, the AST and ALT downregulation levels in the drug-treated group were significantly lower than those in the positive drug group.

[0056] (3) Liver morphology observation, H&E and Masson pathology test: The administration method of each group was the same as the above 2 dose design items. The liver tissues of mice in each group were taken and observed. The results are as follows: Figure 5 As shown. The liver tissues of mice in each group were taken, and the liver tissue samples were fixed with formalin solution, rinsed with water, and liver tissues of appropriate thickness were cut and rinsed with running water for more than 2 hours. The samples of each group were dehydrated using a fully automatic dehydrator. The paraffin-embedded tissues were pre-cooled and then continuously sliced ​​into 4 μm thickness to make slices. The slices were baked in a 60°C oven for more than 2 hours. The samples were dewaxed, hydrated, stained with eosin-hematoxylin (HE), stained with Masson, and sealed with neutral gum and observed under an optical microscope. The final pathological changes of mice in different groups were shown in the figure below. Figure 5 shown.

[0057] Depend on Figure 5 The livers of the control group were smooth, reddish-brown, soft, and elastic, with clear edges. The livers of the model group were brownish-yellow, hard, and blunt, with thick, visible liver margins and numerous small, off-white nodules. After drug intervention, the livers became reddish, softer, and more defined, with a significantly reduced number of nodules. The improvement was most pronounced in the high-dose curcumadiol group, which also achieved superior results compared to the positive drug group.

[0058] H&E and Masson pathology tests revealed that the liver tissue of mice in the normal control group displayed typical physiological structural features, with clear and intact hepatic lobule structure and regular distribution of hepatic cords. Only a small amount of blue-stained collagen fibers were visible in the vascular wall. Compared with the control group, the model group exhibited significant pathological changes, including degenerative changes such as hepatocyte edema and fatty degeneration, disorganized tissue structure, disruption of the normal hepatic lobule structure, marked dilation of the portal region, and the formation of numerous abnormal pseudolobules. Abnormal deposition of blue-stained collagen fibers and extensive formation of fibrous septa were particularly evident in the central venous region. After treatment, liver histological features improved to varying degrees in all treatment groups, with the most significant effect observed in the high-dose protocurdiol group, where hepatocyte structure was well restored and the area of ​​collagen fiber deposition was significantly reduced. The efficacy of the drug-treated group was superior to that of the positive drug group.

[0059] (4) Western blot analysis: The administration method for each group was the same as that for the above-mentioned 2-dose design. The liver tissue of each mouse was taken, 20 mg of liver tissue was weighed, and 100 μL of a mixture (protein lysis buffer: PMSF = 100:1) was added in proportion. Magnetic beads were added and the tissue was homogenized using a tissue cell disruptor. After the homogenization, the tissue was centrifuged for 10 minutes at 15,000 rpm, and the supernatant was collected. The solution was diluted with PBS solution to an appropriate concentration, 5× Loading was added and the mixture was quantified. The mixture was vortexed and the proteins of each group were separated by SDS-PAGE and then transferred to a PVDF membrane. Next, the PVDF membrane was blocked with a 5% skim milk powder-PBST mixture at room temperature for 1 hour. Subsequently, the PVDF membrane was incubated with primary antibodies for α-SMA (1:1000), Collagen I (1:1000), FN (1:1000), and GAPDH (1:15000) at 4°C overnight. After multiple rinses with PBST, the PVDF membrane was incubated with rabbit / mouse secondary antibodies at room temperature for 2 hours. The target protein bands were visualized using the ChemiScope 6100 multi-chemiluminescence imaging system. The changes in liver fibrosis marker proteins in different groups of mice were finally obtained as shown in the following figure. Figure 6 shown.

[0060] Depend on Figure 6 The results showed that compared with the control group, the expression of α-SMA, Collagen I, and Fibronectin proteins in the model group was significantly higher (P<0.001). However, after compound intervention, the expression levels of these proteins decreased, with the effect being most pronounced in the high-dose curcumadiol group.

[0061] (5) Immunofluorescence staining: The administration method of each group was the same as that of the above 2 dose design items, such as Figure 7 Compared with the control group, the model group showed significantly higher fluorescence intensities of α-SMA and Collagen I proteins, with significant deposition of α-SMA and Collagen I proteins in pathologically characteristic areas of the liver (including portal areas, central vein walls, and fibrous septa). However, after compound intervention, the fluorescence intensities of these proteins decreased (P<0.05).

[0062] Example 3 Cellular experiment on the effect of BEX1 knockout and overexpression on the improvement of liver fibrosis by curcuma diol

[0063] 1. Dosage design: Divided into control group, model group, low-dose and high-dose groups of proto-curdodiol. After the cells adhered to the wall, WB-F344 drug treatment was given and cultured in an incubator for 24 hours. The cells were collected for subsequent experiments. The specific drug treatments for each group are as follows: Control group (Control): complete culture medium, Model group (Model): 50ng / mL HGF + complete culture medium, low-dose proto-curdodiol group (Low): 12.5μmol / L Pro + 50ng / mL HGF + complete culture medium, high-dose proto-curdodiol group (High): 25μmol / L Pro + 50ng / mL HGF + complete culture medium.

[0064] 2. Group design: Normal WB-F344 cells and BEX1 knockout WB-F344 cells cultured to the logarithmic growth phase were trypsinized and seeded into six-well plates. The cells were divided into control group, model group, model + drug treatment group, knockout + model group, and knockout + model + drug treatment group.

[0065] 3. Experimental methods and results:

[0066] (1) Western blot experiment of expression of proteins related to hepatic progenitor cell activation: A BEX1 knockout hepatic progenitor cell line was constructed, and the expression levels of marker proteins related to hepatic progenitor cell activation (including SOX9, CK19, DLK1 and EpCAM) were detected by Western blot. Figure 8 As shown in the BEX1 knockout background, proto-curdodiol treatment did not significantly change the expression levels of proteins such as SOX9, CK19, DLK1, and EpCAM (P>0.05). However, after overexpression of BEX1 in hepatic progenitor cells, the expression levels of marker proteins related to hepatic progenitor cell activation, SOX9, CK19, DLK1, and EpCAM, were significantly increased.

[0067] (2) Immunofluorescence staining of hepatic progenitor cell activation-related proteins: Figure 9 As shown in the results, compared with the control group, BEX1 knockout significantly decreased the expression levels of hepatic progenitor cell activation markers (such as Sox9, CK19, and EpCAM) (P < 0.05), indicating that BEX1 gene deletion inhibits the activation of hepatic progenitor cells. At the same time, overexpression of BEX1 in hepatic progenitor cells significantly increased the expression levels of SOX9, CK19, and EpCAM, markers of hepatic progenitor cell activation. This further confirms that BEX1 plays a key regulatory role in the activation of hepatic progenitor cells.

[0068] (3) Transcriptomics experiments before and after BEX1 knockout in hepatic progenitor cell lines: Figure 10As shown, differentially expressed genes (DEGs) were identified between the control, model, and BEX1 knockout groups using the Bioconductor official platform DESeq2 (http: / / bioconductor.org / packages / stats / bioc / DESeq2 / ). Sample PCA plots, histograms of differentially expressed genes, volcano plots of differentially expressed genes, and Venn diagrams of differentially expressed genes were generated. P < 0.05 and log2 (foldchange) > 2 were used as thresholds for differentially expressed genes. In the comparison of "NC vs. NC + HGF," 117 upregulated genes and 130 downregulated genes were identified, for a total of 247 differentially expressed genes. In the comparison of "sgBEX1 + HGF vs. NC + HGF," 149 upregulated genes and 262 downregulated genes were identified, for a total of 411 differentially expressed genes. At the same time, 30 differentially expressed genes were obtained by taking the intersection of the above two comparison groups. KEGG pathway enrichment analysis was further performed on the differentially expressed genes, and it was found that the key signaling pathway regulated after BEX1 knockout was the PI3K / AKT signaling pathway.

[0069] (4) Western-blot experiment of LY294002 inhibiting the expression of inflammatory factor-related proteins: Figure 11 As shown, after the addition of the P-PI3K-specific inhibitor LY294002, the expression levels of inflammatory markers TNF-α, IL-6, and IL-1β were significantly decreased in both normal cells and BEX1 knockout cells, indicating that the PI3K / AKT signaling pathway plays an important regulatory role in the expression of inflammatory factors. Notably, compared with normal cells, the expression of TNF-α, IL-6, and IL-1β in BEX1 knockout cells decreased more significantly (P < 0.001), suggesting that BEX1 regulates the expression of inflammatory factors by regulating the PI3K / AKT signaling pathway. These results indicate that BEX1 not only participates in the regulation of the PI3K / AKT signaling pathway but also plays a key regulatory role in the inflammatory response through this pathway.

[0070] (5) Western blot experiments of proteins related to the PI3K / AKT signaling pathway in hepatic progenitor cells: Figure 12 As shown in the results, compared with the control group, BEX1 knockout significantly decreased the expression levels of proteins in the PI3K / AKT signaling pathway in hepatic progenitor cells (P<0.05), indicating that BEX1 gene deletion inhibits the PI3K / AKT signaling pathway in hepatic progenitor cells. Furthermore, overexpression of BEX1 in hepatic progenitor cells significantly increased the expression levels of proteins in the PI3K / AKT signaling pathway, further confirming that BEX1 / PI3K / AKT plays a key regulatory role in the activation of hepatic progenitor cells.

[0071] (6) Western-blot experiments on the expression of inflammatory factors in BEX1 knockout cell lines: Figure 13 As shown, in BEX1 knockout cell lines, the expression levels of TNF-α, IL-6, and IL-1β were synchronously decreased (P < 0.001); however, in BEX1 overexpressing cell lines, the expression of these inflammatory factors was significantly upregulated (P < 0.001). These positive and negative experimental results fully demonstrate the regulatory role of BEX1 on the expression of inflammatory factors. Further studies found that in BEX1 knockout cell lines, treatment with protocurdiolide did not significantly change the expression levels of TNF-α, IL-6, and IL-1β; however, in BEX1 overexpressing cell lines, protocurdiolide significantly upregulated the expression of these inflammatory factors. These results indicate that BEX1 is a key target for protocurdiolide's anti-inflammatory effects and that protocurdiolide regulates the activity of the PI3K / AKT signaling pathway through a BEX1-mediated mechanism, thereby regulating the expression of inflammatory factors.

[0072] (7) Western blot experiment of epithelial-mesenchymal transition marker proteins of hepatic progenitor cells: Figure 14 As shown in A, after the addition of the P-PI3K specific inhibitor LY294002, the expression levels of EMT-related marker proteins N-cadherin and Vimentin were significantly decreased in normal cells and BEX1 knockout cells (P<0.001, P<0.01), while the expression level of E-cadherin was significantly upregulated (P<0.01). This result indicates that the PI3K / AKT signaling pathway plays an important regulatory role in the EMT process. It is worth noting that the expression of N-cadherin and Vimentin in BEX1 knockout cells also decreased, while the expression of E-cadherin was upregulated (P<0.001). These results suggest that BEX1 further enhances its inhibitory effect on EMT by regulating the PI3K / AKT signaling pathway. Based on the above findings, BEX1 is not only involved in the regulation of the PI3K / AKT signaling pathway, but also plays a key regulatory role in the epithelial-mesenchymal transition process through this pathway. As Figure 14As shown in Figure B, compared with the control group, the expression levels of EMT marker proteins N-cadherin and Vimentin were significantly increased in the model group, while the expression level of E-cadherin was significantly downregulated. In the drug-treated group, the expression of N-cadherin and Vimentin was significantly decreased, while the expression of E-cadherin was significantly upregulated, indicating that protocurdiolide can effectively inhibit the EMT process. To further explore the role of BEX1 in EMT regulation, we conducted tests in BEX1 knockout cell lines. Further studies found that protocurdiolide treatment did not significantly change the expression levels of N-cadherin, Vimentin, and E-cadherin in BEX1 knockout cell lines. These results indicate that BEX1 is a key target of protocurdiolide in regulating the EMT process. Protocurdiolide regulates the activity of the PI3K / AKT signaling pathway through a BEX1-mediated mechanism, thereby affecting the expression of EMT-related proteins.

[0073] (8) Western-blot experiment on the regulation of hepatic progenitor cells by curcuma diol to inhibit the activation of hepatic stellate cells: Figure 15 As shown in the study, hepatic progenitor cells were stimulated with HGF for 24 hours, and their supernatant was then applied to HSCs for 24 hours. Western blot analysis showed that the supernatant of hepatic progenitor cells significantly induced HSC activation, as evidenced by a significant upregulation of the expression levels of the marker proteins α-SMA, Collagen I, and Fibronectin (P < 0.001). However, after treatment with protocurdiodiol, the activation state of HSCs was significantly improved, with a significant decrease in the expression levels of the above-mentioned marker proteins. This result suggests that there is significant intercellular crosstalk between hepatic progenitor cells and hepatic stellate cells, and that protocurdiodiol can inhibit HSC activation by regulating this cellular microenvironment, thereby exerting a potential anti-fibrotic effect.

[0074] Summary: Curcuma zedoariae can significantly inhibit biological processes such as hepatic progenitor cell activation, inflammatory release, epithelial-mesenchymal transition, and hepatic stellate cell activation in a dose-dependent manner, thereby exerting a potential anti-hepatic fibrosis effect. Preparation Example 1: Preparation of Curcuma zedoariae tablets

[0075] Mix 100g of raw curcuma diol, 50g of starch, and 50g of microcrystalline cellulose. Add an appropriate amount of 10% povidone K30 ethanol solution to prepare a soft material. Pass through a 16-mesh sieve to granulate, dry at 60°C, and sieve through an 18-mesh sieve to size the granules. Add 2g of magnesium stearate, mix well, and compress into tablets. Each tablet contains 100mg of raw curcuma diol.

[0076] Preparation Example 2: Preparation of Curcuma zedoariae injection

[0077] Weigh 10 g of raw zedoaryl glycol, dissolve it in 800 ml of water for injection, add 50 g of mannitol as an isotonic regulator, stir to dissolve, add 0.1% activated carbon, stir for 15 minutes, filter, make up to 1000 ml with water for injection, fine filter, fill, and sterilize to obtain the product.

[0078] In summary, the experiment proved that curcumadiol can inhibit the PI3K / AKT signaling pathway by downregulating the expression of brain-expressed X-linked protein 1 (BEX1), thereby inhibiting the release of inflammatory factors and epithelial-mesenchymal transition by liver progenitor cells, inhibiting the activation of hepatic stellate cells, and effectively improving liver function indicators and liver pathological status, thereby achieving the purpose of treating liver fibrosis. Curcumadiol can significantly inhibit the activation of liver progenitor cells, the release of inflammatory factors and epithelial-mesenchymal transition, inhibit the activation and proliferation of hepatic stellate cells in vitro, and significantly reduce the serum transaminase levels and liver fibrosis degree of rats with liver fibrosis model in vivo. The effect of curcumadiol in treating liver fibrosis is better than the common anti-liver fibrosis drugs on the market.

Claims

1. Use of proto-curdodiol in the preparation of a medicament for preventing and / or treating liver fibrosis.

2. The use according to claim 1, characterized in that In the application, proto-curdodiol inhibited the expression of hepatic progenitor cell activation markers (DLK1, EpCAM) in a dose-dependent manner.

3. The use according to claim 1, characterized in that The application is achieved by targeted regulation of BEX1 protein expression in liver progenitor cells and inhibition of excessive activation of the PI3K / AKT signaling pathway.

4. The use according to claim 1, characterized in that In the application, proto-curdodiol inhibited the expression of inflammatory factors (TNF-α, IL-6 and IL-1β) in hepatic progenitor cells in a dose-dependent manner.

5. The use according to claim 1, characterized in that In the application, proto-curdodiol inhibits the expression of epithelial-mesenchymal transition marker proteins (N-cadherin, E-cadherin, Vimentin) of hepatic progenitor cells in a dose-dependent manner.

6. The use according to claim 1, characterized in that The use also includes inhibiting the activation of hepatic stellate cells (HSC).

7. Use of proto-curdodiol in the preparation of a drug for treating liver fibrosis associated with abnormal BEX1 expression, wherein: The drug down-regulated the expression of BEX1 protein in liver tissue by ≥50% (Western blot) and down-regulated the p-AKT / AKT ratio to ±20% of the normal level.

8. The use according to claim 7, characterized in that The serum ALT and AST levels in the drug-treated group decreased by ≥40% compared with the model group, and the collagen area ratio in the liver tissue decreased by ≥60% (Masson staining).

9. A pharmaceutical composition, characterized in that The invention comprises proto-curdodiol as an active ingredient and one or more pharmaceutically acceptable carriers or excipients.

10. The pharmaceutical composition according to claim 9, characterized in that The dosage form of the composition is tablet, capsule, granule or injection.